🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pankaj Kumar

Indian Institute of Technology Guwahati

ORCID: 0000-0003-4284-6787

Also affiliated with Heartland Cancer Research, Illinois CancerCare, National Law University and Judicial Academy

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.241Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae203

Top 61%

0.241DataRank

Top 61%4 citations

Chao Ma, Qian Shi, Félix Couture, Philip Kuebler, Pankaj Kumar +8 more

Papers

Driven by 11 papers — median percentile 39. Top paper: “Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)”.

Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)

Journal of Clinical Oncology(2024)10.1200/jco.23.01680

N/A

0.944DataRank · unranked

25 citations

Tyler S. Twombly, Chao Ma, Qian Shi, Koichiro Haruki, Kenji Fujiyoshi +17 more

Association between physical activity and the time course of cancer recurrence in stage III colon cancer

British Journal of Sports Medicine(2023)10.1136/bjsports-2022-106445

N/A

0.494DataRank · unranked

26 citations

Chao Ma, Qian Shi, Donna Niedzwiecki, Tyler Zemla, Félix Couture +9 more

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Hematological Oncology(2023)10.1002/hon.3163_5

N/A

0.464DataRank · unranked

21 citations

Michael LeBlanc, Sharon M. Castellino, Huilin Li, Sarah C. Rutherford, Andrew M. Evens +41 more

Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0447

N/A

0.360DataRank · unranked

10 citations

Chao Ma, Chen Yuan, Qian Shi, Brian M. Wolpin, Yin Zhang +19 more

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial

The Oncologist(2023)10.1093/oncolo/oyad096

N/A

0.276DataRank · unranked

5 citations

Paul Catalano, Steven J. Cohen, Barbara Burtness, Edith Mitchell, Efrat Dotan +7 more

Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance)

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae203

Top 61%

0.241DataRank

Top 61%4 citations

Chao Ma, Qian Shi, Félix Couture, Philip Kuebler, Pankaj Kumar +8 more

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4003

N/A

0.217DataRank · unranked

3 citations

Qian Shi, Charles S. Fuchs, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar +15 more

Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf281

N/A

0DataRank · unranked

4 citations

Qian Shi, Anthony F. Shields, Xiaonan Xue, Thomas E. Rohan, Chaoyuan Kuang +12 more

Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.10

N/A

0DataRank · unranked

0 citations

Qian Shi, Jeffrey P. Meyers, Zhaohui Jin, Magali Svrcek, Charles S. Fuchs +14 more

Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance)

Cancer(2023)10.1002/cncr.35007

N/A

0DataRank · unranked

4 citations

Chao Ma, Qian Shi, Tyler Zemla, Félix Couture, Philip Kuebler +11 more

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.18_suppl.lba3

N/A

0DataRank · unranked

31 citations

Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina A. Singh +15 more